Renin-angiotensin system (RAS) blockade with angiotensin converting enzyme (ACE) inhibitors or angiotensin II type 1 receptor blockers (ARBs) has turned out to be beneficial at all stages of this ...

Routine use of angiotensin-converting-enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) is recommended in proteinuric nontransplant kidney disease patients, to reduce proteinuria and ...

Warnock led a UAB team that recently found that enzyme-replacement therapy, combined with an ACE inhibitor and angiotensin-receptor blocker (known as ACEI/ARB treatment), can help stop progressive ...

Getting kidney patients to stick with an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) presents a real challenge. Here are some tips that may help.

In addition to their capacity to lower systemic blood pressure, angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-II receptor blockers (ARBs) are thought to have specific ...

Large secondary prevention trials suggest that dual RAS blockade is not generally indicated for the prevention of CHF in Stage A/B patients, since ARBs and ACE inhibitors are equal with respect to ...

Getting kidney patients to stick with an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) presents a real challenge. Here are some tips that may help.